Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOVA22007 dose-ranging randomized double-blind phase II/III study in vernal keratoconjunctivitis
2006-000319-96Phase 2Completed
- Sponsor
- Novagali Pharma
- Start
- Apr 2006
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NOVA22007 and cyclosporine in Vernal Keratoconjunctivitis (VKC) (3 arms), sponsored by Novagali Pharma. Primary endpoint: Primary efficacy endpoint. Started Apr 2006; status: completed.
02
Drugs
NOVA22007cyclosporine
03
Conditions
Vernal Keratoconjunctivitis (VKC)
Beyond the preview
Go deeper on 2006-000319-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000319-96.